Laekna Therapeutics Shanghai Co., Ltd, a China-based pharmaceutical company, has announced topline data from the global multi-center Phase II PROFECTA-II study for its afuresertib combined with paclitaxel in the treatment of platinum-resistant ovarian cancer (PROC). The Sino-US study aimed to assess the efficacy and safety of the combination therapy in PROC, and the results indicated that while the combination of afuresertib and paclitaxel reduced the risk of disease progression or death, it did not achieve statistical significance across all participants. However, in the biomarker-positive subgroup characterized by AKT phosphorylation, the afuresertib combination group saw a significant improvement in progression-free survival (mPFS: 5.4 months vs 2.9 months). The safety profile of the combination was manageable and tolerable, aligning with the known safety characteristics of the drug.
Afuresertib, a highly selective AKT kinase inhibitor licensed from Novartis, is under investigation in multiple clinical studies for use in combination with other drugs in various cancers, including breast, prostate, ovarian, and solid tumors resistant to PD-1/PD-L1 inhibitors.- Flcube.com
